There are several different agents that can be used for gastrointestinal (GI) ulcer prophylaxis in posttransplant recipients, such as histamine-2 receptor antagonists (H2RA) or proton pump inhibitors (PPIs).
Research Question:
This study was conducted to compare the incidence of adverse kidney events in transplant recipients who received prophylaxis with H2RAs or PPIs.
Design:
This retrospective study included all kidney transplant recipients from 3 transplant centers who were transplanted in 2009 through 2011. The primary objective was to compare the incidence of adverse events posttransplant, defined as the incidence of pneumonia, Clostridium difficile, hip fractures, GI bleeding, cytomegalovirus, organ rejection, and bacteremia.
Results:
A total of 211 patients were included in the study; of which 35 were included in the PPI group and 176 were included in the H2RA group. There were no significant differences between groups in regard to incidence of GI bleeding events or other adverse events.
Discussion:
These findings suggest there is a low incidence of GI ulcers and upper GI bleeding events after kidney transplantation with the use of H2RAs or PPIs. Additionally, there are similar rates of adverse events when comparing H2RAs versus PPIs for GI ulcer prophylaxis.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1–S24.
2.
DaleyRJRebuckJAWelageLSRogersFB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32(10):2008–2013.
3.
QuenotJPThieryNBarbarS. When should stress ulcer prophylaxis be used in the ICU?Curr Opin Crit Care. 2009;15(2):139–143. doi:10.1097/MCC.0b013e32832978e0.
4.
LaineLJensenDM. Management of patient with ulcer bleeding. Am J Gastroenterol. 2012:107(3):345–360. doi:10.1038/ajg.2011.480.
5.
ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347–379.
6.
MartindaleRG. Contemporary strategies for the prevention of stress-related mucosal bleeding. Am J Health Syst Pharm. 2005;62(10 suppl 2):S11–S17.
7.
CookDJFullerHDGuyattGH. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):337–381.
8.
RupprechtKSchmidtCRaspeA. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49(10):1196–1201. doi:10.1177/0091270009344988.
9.
KoflerSWolfeCShvetsN. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565–571. doi:10.1016/j.healun.2010.12.003.
10.
KoflerSDeutschMABigdeliAK. Proton pump inhibitor co-medication reduced mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28(6):605–611. doi:10.1016/j.healun.2009.03.006.
11.
KoflerSShvetsNBigdeliAK. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study. Am J Transplant. 2009;9(7):1650–1666. doi:10.1111/j.1600-6143.2009.02682.x.
12.
CookDHeylandDGriffithLCookRMarshallJPagliarelloJ. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27(12):2812–2817.
13.
MurphyCEStevensAMFerrentinoN. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy. 2008;28(8):968–976. doi:10.1592/phco.28.8.968.
14.
DialDAlrasadiKManoukianCHuangAMenziesD. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171(1):33–38.
15.
LaheijRJFSturkenboomMCHassingRJDielemanJStrickerBHJansenJB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.
16.
GulmezSEHolmAFrederiksenHJensenTGPedersenCHallasJ. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population based case–control study. Arch Intern Med. 2007;167(9):950–955.
17.
YangYXLewisJDEpsteinSMetzDC. Long-term proton pump inhibitor therapy and the risk of hip fracture. JAMA. 2006;296(24):2947–2953.
VincentiFJensikSCFiloRSMillerJPirschJ. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–782.
26.
PirschJDMillerJDeierhoiMHVincentiFFiloRS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Group. Transplantation. 1997;63(7):977–983.
27.
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) OPTN/SRTR 2011 annual data report. Rockville, MD: Department of Health and Human Services; 2012.
28.
Lexi-Comp Online, Tacrolimus [package insert]. Hudson, OH: Lexi-Comp Inc. Updated periodically. Accessed September 2016.
29.
StaatzCETettSE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58.
30.
KnorrJPSjeimeMBraitmanLEJawaPZakiROrtizJ. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518–524. doi:10.1097/01.tp.0000436100.65983.10.
